Shattuck Labs vs Spyre Therapeutics
STTK and SYRE side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How STTK and SYRE compare
Spyre Therapeutics is the larger company, worth 15 times as much as Shattuck Labs ($8.5B against $558M).
Shattuck Labs scores higher on the StockData Score (9 against 7 for Spyre Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | STTK | SYRE |
|---|---|---|
| Size and price | ||
| Market cap | $558M | $8.5B |
| Share price | $5.56 | $96.56 |
| Change, 1 year | 185% | 305% |
| Change, 5 years | −69.9% | −47.2% |
| Beta (5Y) | 1.60 | 1.47 |
| Employees | 40 | 102 |
| StockData Score | ||
| Total score | 9 (better) | 7 |
| Valuation score | 0 | 0 |
| Growth score | 1 (better) | 0 |
| Performance score | 2 (better) | 1 |
| Health score | 6 | 6 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 558× | – |
| P/B | 2.6× (better) | 7.7× |
| Growth | ||
| Revenue growth (TTM) | −66.6% | – |
| Revenue growth, 5Y average | −36.8% | – |
| Profitability | ||
| Operating margin | −5579% | – |
| Net margin | −5257% | – |
| Return on equity | −39.2% | −23.0% (better) |
| Return on invested capital | −942% | – |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 27.59 (better) | 18.53 |
| Altman Z-score | 32.50 | 70.18 (better) |
| Piotroski F-score | 4 | 4 |
| Dividends and buybacks | ||
| Buyback yield | −26.1% | – |
| Shareholder yield | −26.1% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 83.5% | 109% |
| Held by insiders | 24.1% | 20.4% |
| Insider net buying, 12 months | −$342K (better) | −$437M |
| Short interest, % of float | 14.4% | 18.3% |
Go deeper
- STTK stock overview
- STTK income statement
- STTK valuation and score
- SYRE stock overview
- SYRE income statement
- SYRE valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.